Searching for target-specific and multi-targeting organics for Covid-19 in the Drugbank database with a double scoring approach

[1]  R. Ahuja,et al.  Structure-based drug designing and immunoinformatics approach for SARS-CoV-2 , 2020, Science Advances.

[2]  Chitra Jeyaraj Pandian,et al.  Computational investigation on Andrographis paniculata phytochemicals to evaluate their potency against SARS-CoV-2 in comparison to known antiviral compounds in drug trials , 2020, Journal of biomolecular structure & dynamics.

[3]  Vijay Kumar Bhardwaj,et al.  Identification of bioactive molecules from tea plant as SARS-CoV-2 main protease inhibitors , 2020, Journal of biomolecular structure & dynamics.

[4]  Junmei Wang,et al.  Fast Identification of Possible Drug Treatment of Coronavirus Disease-19 (COVID-19) through Computational Drug Repurposing Study , 2020, Journal of chemical information and modeling.

[5]  Durkin,et al.  Structure-Based Virtual Screening of a Natural Product Database to Identify Several Possible SARS-CoV-2 Main Protease Inhibitors , 2020 .

[6]  Asher Mullard.  Flooded by the torrent: the COVID-19 drug pipeline , 2020, The Lancet.

[7]  J. Avorn,et al.  Drug Evaluation during the Covid-19 Pandemic. , 2020, The New England journal of medicine.

[8]  Hualiang Jiang,et al.  Structure of Mpro from SARS-CoV-2 and discovery of its inhibitors , 2020, Nature.

[9]  M. Michael Gromiha,et al.  Computational studies of drug repurposing and synergism of lopinavir, oseltamivir and ritonavir binding with SARS-CoV-2 protease against COVID-19 , 2020, Journal of biomolecular structure & dynamics.

[10]  A. Scala,et al.  Putative Inhibitors of SARS-CoV-2 Main Protease from A Library of Marine Natural Products: A Virtual Screening and Molecular Modeling Study , 2020, Marine drugs.

[11]  A. Shehata,et al.  The COVID-19 Pandemic: A Comprehensive Review of Taxonomy, Genetics, Epidemiology, Diagnosis, Treatment, and Control , 2020, Journal of clinical medicine.

[12]  E. Holmes,et al.  A Genomic Perspective on the Origin and Emergence of SARS-CoV-2 , 2020, Cell.

[13]  A. Scala,et al.  Inhibitors of SARS-CoV-2 Main Protease from a Library of Marine Natural Products: A Virtual Screening and Molecular Modeling Study , 2020 .

[14]  Dhruv Kumar,et al.  In Silico Identification of Potent COVID-19 Main Protease Inhibitors from FDA Approved Antiviral Compounds and Active Phytochemicals through Molecular Docking: A Drug Repurposing Approach , 2020 .

[15]  D. Raoult,et al.  Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial , 2020, International Journal of Antimicrobial Agents.

[16]  Yuan Wei,et al.  A Trial of Lopinavir–Ritonavir in Adults Hospitalized with Severe Covid-19 , 2020, The New England journal of medicine.

[17]  M. Lipsitch,et al.  Estimating clinical severity of COVID-19 from the transmission dynamics in Wuhan, China , 2020, Nature Medicine.

[18]  R. Awaluddin,et al.  Potential Inhibitor of COVID-19 Main Protease (Mpro) From Several Medicinal Plant Compounds by Molecular Docking Study , 2020 .

[19]  Cynthia Liu,et al.  Research and Development on Therapeutic Agents and Vaccines for COVID-19 and Related Human Coronavirus Diseases , 2020, ACS central science.

[20]  D. Raoult,et al.  New insights on the antiviral effects of chloroquine against coronavirus: what to expect for COVID-19? , 2020, International Journal of Antimicrobial Agents.

[21]  Qiang Zhou,et al.  Structural basis for the recognition of SARS-CoV-2 by full-length human ACE2 , 2020, Science.

[22]  A. Elfiky,et al.  Anti-HCV, nucleotide inhibitors, repurposing against COVID-19 , 2020, Life Sciences.

[23]  Hualiang Jiang,et al.  Structure of Mpro from COVID-19 virus and discovery of its inhibitors , 2020, bioRxiv.

[24]  Charlotte Harrison,et al.  Coronavirus puts drug repurposing on the fast track , 2020, Nature Biotechnology.

[25]  T. Phan,et al.  Genetic diversity and evolution of SARS-CoV-2 , 2020, Infection, Genetics and Evolution.

[26]  Young-Jun Park,et al.  Structure, Function, and Antigenicity of the SARS-CoV-2 Spike Glycoprotein , 2020, Cell.

[27]  B. Graham,et al.  Cryo-EM structure of the 2019-nCoV spike in the prefusion conformation , 2020, Science.

[28]  J. Rocklöv,et al.  The reproductive number of COVID-19 is higher compared to SARS coronavirus , 2020, Journal of travel medicine.

[29]  A. Contini,et al.  Virtual Screening of an FDA Approved Drugs Database on Two COVID-19 Coronavirus Proteins , 2020 .

[30]  A. Contini.  Virtual Screening of an FDA Approved Drugs Database on Two COVID-19 Coronavirus Proteins , 2020 .

[31]  T. Dörner,et al.  Mechanisms of action of hydroxychloroquine and chloroquine: implications for rheumatology , 2020, Nature Reviews Rheumatology.

[32]  E. Holmes,et al.  A new coronavirus associated with human respiratory disease in China , 2020, Nature.

[33]  A. Phelan,et al.  Baricitinib as potential treatment for 2019-nCoV acute respiratory disease , 2020, The Lancet.

[34]  R. Shafer,et al.  2019 update of the drug resistance mutations in HIV-1. , 2019, Topics in antiviral medicine.

[35]  S. Ekins,et al.  New targets for HIV drug discovery. , 2019, Drug discovery today.

[36]  K. Vishwanathan,et al.  Single-Dose Pharmacokinetics, Excretion, and Metabolism of Zoliflodacin, a Novel Spiropyrimidinetrione Antibiotic, in Healthy Volunteers , 2018, Antimicrobial Agents and Chemotherapy.

[37]  D. Goldhill,et al.  The mechanism of resistance to favipiravir in influenza , 2018, Proceedings of the National Academy of Sciences.

[38]  J. H. Zhang,et al.  Assessing the performance of MM/PBSA and MM/GBSA methods. 7. Entropy effects on the performance of end-point binding free energy calculation approaches. , 2018, Physical chemistry chemical physics : PCCP.

[39]  Torsten Schwede,et al.  SWISS-MODEL: homology modelling of protein structures and complexes , 2018, Nucleic Acids Res..

[40]  Weilin Zhang,et al.  Computational Multitarget Drug Design , 2017, J. Chem. Inf. Model..

[41]  S. Perlman,et al.  Coronaviruses: An Overview of Their Replication and Pathogenesis , 2015, Methods in molecular biology.

[42]  Youyong Li,et al.  Assessing the performance of MM/PBSA and MM/GBSA methods. 5. Improved docking performance using high solute dielectric constant MM/GBSA and MM/PBSA rescoring. , 2014, Physical chemistry chemical physics : PCCP.

[43]  D. Smee,et al.  Favipiravir (T-705), a novel viral RNA polymerase inhibitor. , 2013, Antiviral research.

[44]  W. Tong,et al.  In silico drug repositioning: what we need to know. , 2013, Drug discovery today.

[45]  M. Sieńczyk,et al.  Viral proteases as targets for drug design. , 2012, Current pharmaceutical design.

[46]  Giulio Rastelli,et al.  Application of a post-docking procedure based on MM-PBSA and MM-GBSA on single and multiple protein conformations. , 2012, European journal of medicinal chemistry.

[47]  Holger Gohlke,et al.  MMPBSA.py: An Efficient Program for End-State Free Energy Calculations. , 2012, Journal of chemical theory and computation.

[48]  Xiaohong Liu,et al.  The HCV Non-Nucleoside Inhibitor Tegobuvir Utilizes a Novel Mechanism of Action to Inhibit NS5B Polymerase Function , 2012, PloS one.

[49]  Scott Federhen,et al.  The NCBI Taxonomy database , 2011, Nucleic Acids Res..

[50]  W. Sadee.  Genomics and personalized medicine. , 2011, International journal of pharmaceutics.

[51]  Tingjun Hou,et al.  Assessing the performance of the molecular mechanics/Poisson Boltzmann surface area and molecular mechanics/generalized Born surface area methods. II. The accuracy of ranking poses generated from docking , 2011, J. Comput. Chem..

[52]  Giulio Rastelli,et al.  Fast and accurate predictions of binding free energies using MM‐PBSA and MM‐GBSA , 2009, J. Comput. Chem..

[53]  Peter Ertl,et al.  Estimation of synthetic accessibility score of drug-like molecules based on molecular complexity and fragment contributions , 2009, J. Cheminformatics.

[54]  Lorenz C. Blum,et al.  970 million druglike small molecules for virtual screening in the chemical universe database GDB-13. , 2009, Journal of the American Chemical Society.

[55]  A. Olson,et al.  AutoDock Vina: Improving the speed and accuracy of docking with a new scoring function, efficient optimization, and multithreading , 2009, J. Comput. Chem..

[56]  J. Remon,et al.  Development of fixed dose combination tablets containing zidovudine and lamivudine for paediatric applications. , 2009, International journal of pharmaceutics.

[57]  Michael Entzeroth,et al.  Overview of High‐Throughput Screening , 2009, Current protocols in pharmacology.

[58]  H. Gunthard,et al.  Update of the Drug Resistance Mutations in HIV-1. , 2008, Topics in HIV medicine : a publication of the International AIDS Society, USA.

[59]  H. Riezman,et al.  Natamycin Blocks Fungal Growth by Binding Specifically to Ergosterol without Permeabilizing the Membrane* , 2008, Journal of Biological Chemistry.

[60]  David S. Wishart,et al.  DrugBank: a knowledgebase for drugs, drug actions and drug targets , 2007, Nucleic Acids Res..

[61]  Matthew R. Lee,et al.  Improving Docking Accuracy through Molecular Mechanics Generalized Born Optimization and Scoring. , 2007, Journal of chemical theory and computation.

[62]  P. Hajduk,et al.  A decade of fragment-based drug design: strategic advances and lessons learned , 2007, Nature Reviews Drug Discovery.

[63]  Haruki Nakamura,et al.  The worldwide Protein Data Bank (wwPDB): ensuring a single, uniform archive of PDB data , 2006, Nucleic Acids Res..

[64]  David J. Lipman,et al.  A global initiative on sharing avian flu data , 2006, Nature.

[65]  Gisbert Schneider,et al.  Computer-based de novo design of drug-like molecules , 2005, Nature Reviews Drug Discovery.

[66]  Péter Csermely,et al.  The efficiency of multi-target drugs: the network approach might help drug design. , 2004, Trends in pharmacological sciences.

[67]  D. Noe,et al.  A Phase I Open Label Study of the Farnesyltransferase Inhibitor CP-609,754 in Patients with Advanced Malignant Tumors , 2004, Clinical Cancer Research.

[68]  Junmei Wang,et al.  Development and testing of a general amber force field , 2004, J. Comput. Chem..

[69]  Natasja Brooijmans,et al.  Molecular recognition and docking algorithms. , 2003, Annual review of biophysics and biomolecular structure.

[70]  J. Irwin,et al.  Lead discovery using molecular docking. , 2002, Current opinion in chemical biology.

[71]  Pickett,et al.  Computational methods for the prediction of 'drug-likeness' , 2000, Drug discovery today.

[72]  J. Falloon,et al.  JE-2147: a dipeptide protease inhibitor (PI) that potently inhibits multi-PI-resistant HIV-1. , 1999, Proceedings of the National Academy of Sciences of the United States of America.

[73]  David S. Goodsell,et al.  Automated docking using a Lamarckian genetic algorithm and an empirical binding free energy function , 1998, J. Comput. Chem..

[74]  K Schulten,et al.  VMD: visual molecular dynamics. , 1996, Journal of molecular graphics.

[75]  J M Thornton,et al.  LIGPLOT: a program to generate schematic diagrams of protein-ligand interactions. , 1995, Protein engineering.

[76]  Holger Gohlke,et al.  MMPBSA . py : An E ffi cient Program for End-State Free Energy Calculations , 2012 .

[77]  Giovanni Scalmani,et al.  Gaussian 09W, revision A. 02 , 2009 .

[78]  Brian K. Shoichet,et al.  ZINC - A Free Database of Commercially Available Compounds for Virtual Screening , 2005, J. Chem. Inf. Model..